Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bo Gou

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Natural Products and Bioprospecting|February 5, 2025
Design, synthesis and biological evaluation of buthutin derivatives as cardioprotective agentsYuan Liu, Fa-Qi Wang, Xin-Hao Hua, et al.
Therapeutic Advances in Gastroenterology|May 5, 2022
Linaclotide for treating patients with irritable bowel syndrome with predominant constipation: a multicentre study of real-world data in ChinaLan Liu, Weihao Zhang, Wei Zhao, et al.
The Lancet. Infectious Diseases|June 23, 2023
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trialJing-Xin Li, Li-Hua Hou, Jin-Bo Gou, et al.
Emerging Microbes & Infections|November 7, 2023
Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trialJia-Wei Xu, Bu-Sen Wang, Ping Gao, et al.
The Lancet. Infectious Diseases|May 22, 2023
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trialJun-Dong Wu, Jing-Xin Li, Jian Liu, et al.
Lancet (London, England)|May 26, 2020
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trialFeng-Cai Zhu, Yu-Hua Li, Xu-Hua Guan, et al.
The Lancet. Respiratory Medicine|March 10, 2023
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trialRong Tang, Hui Zheng, Bu-Sen Wang, et al.
The Lancet. Respiratory Medicine|May 20, 2023
Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre studyTao Huang, Sheng Zhang, De-Fang Dai, et al.
The Lancet Regional Health. Western Pacific|June 26, 2023
Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trialPeng-Fei Jin, Xi-Ling Guo, Jin-Bo Gou, et al.
Lancet (London, England)|July 24, 2020
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trialFeng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Natural Products and Bioprospecting|February 5, 2025
Design, synthesis and biological evaluation of buthutin derivatives as cardioprotective agentsYuan Liu, Fa-Qi Wang, Xin-Hao Hua, et al.
Therapeutic Advances in Gastroenterology|May 5, 2022
Linaclotide for treating patients with irritable bowel syndrome with predominant constipation: a multicentre study of real-world data in ChinaLan Liu, Weihao Zhang, Wei Zhao, et al.
The Lancet. Infectious Diseases|June 23, 2023
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trialJing-Xin Li, Li-Hua Hou, Jin-Bo Gou, et al.
Emerging Microbes & Infections|November 7, 2023
Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trialJia-Wei Xu, Bu-Sen Wang, Ping Gao, et al.
The Lancet. Infectious Diseases|May 22, 2023
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trialJun-Dong Wu, Jing-Xin Li, Jian Liu, et al.
Lancet (London, England)|May 26, 2020
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trialFeng-Cai Zhu, Yu-Hua Li, Xu-Hua Guan, et al.
The Lancet. Respiratory Medicine|March 10, 2023
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trialRong Tang, Hui Zheng, Bu-Sen Wang, et al.
The Lancet. Respiratory Medicine|May 20, 2023
Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre studyTao Huang, Sheng Zhang, De-Fang Dai, et al.
The Lancet Regional Health. Western Pacific|June 26, 2023
Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trialPeng-Fei Jin, Xi-Ling Guo, Jin-Bo Gou, et al.
Lancet (London, England)|July 24, 2020
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trialFeng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li, et al.
Pageof 7